In the last trading session, 3.68 million shares of the Seres Therapeutics Inc (NASDAQ:MCRB) were traded, and its beta was 2.31. Most recently the company’s share price was $0.56, and it changed around -$0.02 or -4.16% from the last close, which brings the market valuation of the company to $84.55M. MCRB currently trades at a discount to its 52-week high of $6.73, offering almost -1101.79% off that amount. The share price’s 52-week low was $0.58, which indicates that the current value has fallen by an impressive -3.57% since then. We note from Seres Therapeutics Inc’s average daily trading volume that its 3-month average coming to 3.90 million.
Seres Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.86. If we narrow it down even further, the data shows that 0 out of 9 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 2 recommended MCRB as a Hold, whereas 4 deemed it a Buy, and 0 rated it as Underweight. Seres Therapeutics Inc is expected to report earnings per share of $Monarch Casino & Resort, Inc. for the current quarter.
Seres Therapeutics Inc (NASDAQ:MCRB) trade information
Instantly MCRB has showed a red trend with a performance of -4.16% at the end of last trading. The performance over the last five days has remained in the red territory. The company’s shares are currently down -60.01% year-to-date, but still down -14.48% over the last five days. On the other hand, Seres Therapeutics Inc (NASDAQ:MCRB) is -32.65% down in the 30-day period.
Seres Therapeutics Inc (MCRB) estimates and forecasts
Seres Therapeutics Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -58.53 percent over the past six months and at a -29.21% annual growth rate that is well below the industry average of 13.30%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 18.22%.
MCRB Dividends
Seres Therapeutics Inc’s next quarterly earnings report is expected to be released in May.
